|
|
 |
|
Viewing report
|
|
|
|
Psychiatric Drugs: New Developments and Market Analysis by Drug Class and Clinical Indication
Drug and Market Development Publishing, Nov 2004, Pages: 250
In the U.S. alone, it is estimated that 22.1% of adults ages 18 and older (about 45 million) suffer from a diagnosable psychiatric (or mental) disorder.
Pharmacologic treatment of psychiatric indications is evolving, as the number of new compounds in development for these indications continues to grow, enabled by basic neuroscience research and pharmaceutical R&D efforts that are broad and deep. During the last two decades many new drugs for psychiatric indications have been introduced, paradigm shifts in treatment of major disorders have occurred, and huge and expanding pharmaceutical markets have emerged.
Because of the great cross-over of psych drug classes into many different clinical applications, the Report is broken out into two major sections - drug classes and clinical markets. The Report reviews drugs in the pipeline and provides a sophisticated analysis of changing clinical practices, market dynamics, and informed projections. This Report provides a large database of important classes of psychiatric drugs in development and the multiple indications for which they will be used. In addition, the Report includes a sophisticated analysis of clinical trends (such as and combination drug therapy) and market dynamics.
Market Opportunities
Create atypical antipsychotics for bipolar and other indications, which account for far greater sales than the schizophrenia indication
Produce antiepileptic drugs for bipolar, neuropathic pain, and other indications, which account for far greater sales than epilepsy indications
Develop cognitive / memory enhancing compounds for Alzheimer's disease and mild cognitive impairment, a potentially huge new market
Wake-promoting drugs for narcolepsy are in development for and/or obtaining approvals for stimulant-type indications (including ADHD) and have created an entirely new indication - excessive daytime sleepiness - with huge market potential
Key Reasons to Buy This Report
Gain comprehensive insight across the various drug classes with an overview of the ten major psychiatric drugs including tables of drugs in development and in clinical trials, important R&D trends, critical upcoming developments, markets, and market drivers.
Learn about clinical market trends via a thorough analysis of the nine major psychiatric indications including basic definitions, etiology, prevalence estimates, and current therapies.
Look inside 58 companies who are involved in psychiatric drug development from small companies developing only a few drugs to major pharmaceutical companies developing a dozen to more than 20 drugs for psychiatric indications.
This Report Answers These Crucial Industry Questions
What is the status of new drugs in development by drug class and clinical indication?
Which drugs are promising for which (potentially multiple) clinical indications?
How are multiple indications having an impact on new drug development and pursuit of new, multiple market opportunities?
What are the new and upcoming compounds with novel mechanisms of action and new, potentially, first-in-class compounds, and how soon will they have a clinical market impact?
Will new compounds sustain the remarkable growth experienced by psychiatric drugs during the last two decades, or is market stagnation or decline an inevitable result of generic competition?
What are the potential applications and market opportunities for psychiatric drugs by drug class?
What drugs are competing for the same indications?
In which clinical markets are drugs from disparate drug classes having a current impact and how will these markets change during the next 5 to 10 years?
Company Profiles Include:
Abbott Laboratories, Inc.
Addex Pharmaceuticals SA
Alkermes, Inc.
Amarin Corporation plc
AstraZeneca PLC
Avanir Pharmaceuticals, Inc.
Aventis, Aventis Pasteur
Axonyx, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co.
Celltech Group plc
Cephalon, Inc.
Cortex Pharmaceuticals, Inc.
Dainippon
DOV Pharmaceutical, Inc.
DrugAbuse Pharmaceuticals, Inc.
Elan Corporation plc
Eli Lilly and Company
Forest Laboratories, Inc.
GB Therapeutics Ltd.
GlaxoSmithKline plc
Helicon Therapeutics, Inc.
Indevus Pharmaceuticals, Inc.
Innapharma, Inc.
Johnson & Johnson (including Janssen Pharmaceutica, Janssen-Cilag Alza, Ortho-McNeil)
Laxdale, Ltd.
Lundbeck (H. Lundbeck A/S)
MediciNova, Inc.
Memory Pharmaceuticals Corporation
Merck & Co., Inc.
Merck KgaA
Nabi Biopharmaceuticals, Inc.
Nastech Pharmaceutical Co., Inc.
Neurocrine Biosciences, Inc.
Neurogen Corporation
NeuroSearch A/S
Novartis AG
Organon International (Akzo Nobel)
Orphan Medical, Inc.
Otsuka Group
Pfizer, Inc.
Pierre Fabre SA
Predix Pharmaceuticals, Inc.
Roche (F. Hoffmann-La Roche, Ltd.)
Saegis Pharmaceuticals, Inc.
Sanofi-Aventis (formerly Sanofi-Synthélabo)
Sention, Inc.
Sepracor, Inc.
Servier S.A
Solvay S.A.
Somerset Pharmaceuticals, Inc. (Watson/ Mylan joint venture)
Takeda Pharmaceutical Company Ltd
Titan Pharmaceuticals, Inc.
Vela Pharmaceuticals Inc.
Wex Pharmaceuticals Inc.
Wyeth, Inc.
Xenova Group PLC
Yamanouchi Pharmaceutical Co., Ltd
Customers who bought this item also bought
Anxiety Disorders - Viable Indication for Antipsychotics Companies
Pharmacogenomics for Clinical Use and in Drug Development
Lifestyle Drugs Market Outlook: Key Indications, Epidemiology, and Emergent Drugs
Anxiety Disorders - A Decade of Declining Revenues
Emerging Diagnostic Technologies for Use in Psychiatric Indications
Pain Therapeutics - Drugs, Markets and Companies
Infectious Diseases Drugs Markets
Handbook of Psychiatric Drugs
Are There Changes Ahead for the Generalized Anxiety Disorder Market?
Neuroprotection - Drugs, Markets and Companies
Angiotensin as a target for the treatment of Alzheimer's disease, anxiety and depression
Drugs in the Pipeline--An R&D Analysis
|
|
|
|
